Glucocorticoid receptor confers resistance to antiandrogens by bypassing androgen receptor blockade
- PMID: 24315100
- PMCID: PMC3932525
- DOI: 10.1016/j.cell.2013.11.012
Glucocorticoid receptor confers resistance to antiandrogens by bypassing androgen receptor blockade
Abstract
The treatment of advanced prostate cancer has been transformed by novel antiandrogen therapies such as enzalutamide. Here, we identify induction of glucocorticoid receptor (GR) expression as a common feature of drug-resistant tumors in a credentialed preclinical model, a finding also confirmed in patient samples. GR substituted for the androgen receptor (AR) to activate a similar but distinguishable set of target genes and was necessary for maintenance of the resistant phenotype. The GR agonist dexamethasone was sufficient to confer enzalutamide resistance, whereas a GR antagonist restored sensitivity. Acute AR inhibition resulted in GR upregulation in a subset of prostate cancer cells due to relief of AR-mediated feedback repression of GR expression. These findings establish a mechanism of escape from AR blockade through expansion of cells primed to drive AR target genes via an alternative nuclear receptor upon drug exposure.
Copyright © 2013 Elsevier Inc. All rights reserved.
Figures
![Figure 1](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/3932525/bin/nihms-550477-f0001.gif)
![Figure 2](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/3932525/bin/nihms-550477-f0002.gif)
![Figure 3](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/3932525/bin/nihms-550477-f0003.gif)
![Figure 4](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/3932525/bin/nihms-550477-f0004.gif)
![Figure 5](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/3932525/bin/nihms-550477-f0005.gif)
![Figure 6](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/3932525/bin/nihms-550477-f0006.gif)
![Figure 7](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/3932525/bin/nihms-550477-f0007.gif)
Comment in
-
Reappraisal of glucocorticoids in castrate-resistant prostate cancer.Asian J Androl. 2014 Sep-Oct;16(5):666. doi: 10.4103/1008-682X.133314. Asian J Androl. 2014. PMID: 24994787 Free PMC article.
Similar articles
-
Design and Synthesis of Dual-Target Inhibitors Targeting Androgen Receptors and Glucocorticoid Receptors to Overcome Antiandrogen Resistance in Castration-Resistant Prostate Cancer.J Med Chem. 2024 Mar 14;67(5):3419-3436. doi: 10.1021/acs.jmedchem.3c01668. Epub 2024 Feb 22. J Med Chem. 2024. PMID: 38385428
-
Is the glucocorticoid receptor a key player in prostate cancer?: A literature review.Medicine (Baltimore). 2022 Jul 22;101(29):e29716. doi: 10.1097/MD.0000000000029716. Medicine (Baltimore). 2022. PMID: 35866830 Free PMC article. Review.
-
Non-Steroidal Androgen Receptor Antagonists and Prostate Cancer: A Survey on Chemical Structures Binding this Fast-Mutating Target.Curr Med Chem. 2019;26(33):6053-6073. doi: 10.2174/0929867325666180913095239. Curr Med Chem. 2019. PMID: 30209993 Review.
-
Reappraisal of glucocorticoids in castrate-resistant prostate cancer.Asian J Androl. 2014 Sep-Oct;16(5):666. doi: 10.4103/1008-682X.133314. Asian J Androl. 2014. PMID: 24994787 Free PMC article.
-
Glucocorticoid receptor activity contributes to resistance to androgen-targeted therapy in prostate cancer.Horm Cancer. 2014 Apr;5(2):72-89. doi: 10.1007/s12672-014-0173-2. Epub 2014 Mar 11. Horm Cancer. 2014. PMID: 24615402 Free PMC article.
Cited by
-
Regulation of Molecular Biomarkers Associated with the Progression of Prostate Cancer.Int J Mol Sci. 2024 Apr 10;25(8):4171. doi: 10.3390/ijms25084171. Int J Mol Sci. 2024. PMID: 38673756 Free PMC article. Review.
-
Plexin D1 emerges as a novel target in the development of neural lineage plasticity in treatment-resistant prostate cancer.Res Sq [Preprint]. 2024 Mar 27:rs.3.rs-4095949. doi: 10.21203/rs.3.rs-4095949/v1. Res Sq. 2024. Update in: Oncogene. 2024 Jun 14. doi: 10.1038/s41388-024-03081-6. PMID: 38585965 Free PMC article. Updated. Preprint.
-
EP300/CREBBP acetyltransferase inhibition limits steroid receptor and FOXA1 signaling in prostate cancer cells.Cell Mol Life Sci. 2024 Apr 2;81(1):160. doi: 10.1007/s00018-024-05209-z. Cell Mol Life Sci. 2024. PMID: 38564048 Free PMC article.
-
Dexamethasone inhibits androgen receptor-negative prostate cancer cell proliferation via the GR-FOXO3a-GAS5 axis.Heliyon. 2024 Mar 8;10(6):e27568. doi: 10.1016/j.heliyon.2024.e27568. eCollection 2024 Mar 30. Heliyon. 2024. PMID: 38496836 Free PMC article.
-
Targeting monoamine oxidase A: a strategy for inhibiting tumor growth with both immune checkpoint inhibitors and immune modulators.Cancer Immunol Immunother. 2024 Feb 13;73(3):48. doi: 10.1007/s00262-023-03622-0. Cancer Immunol Immunother. 2024. PMID: 38349393 Free PMC article. Review.
References
-
- Chen CD, Welsbie DS, Tran C, Baek SH, Chen R, Vessella R, Rosenfeld MG, Sawyers CL. Molecular determinants of resistance to antiandrogen therapy. Nat Med. 2004;10:33–39. - PubMed
Publication types
MeSH terms
Substances
Associated data
- Actions
- Actions
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials